Glycosylation is an important product quality attribute for biotherapeutic proteins expressed in CHO cells. Glycoform variability can significantly affect the safety and efficacy of therapeutic proteins, and can be dependent on several factors, including cell line, media/feeds, and process. As a consequence, it has often been challenging to achieve and maintain preferred glycosylation profiles from cell culture development through bioreactor scale-up. To address these challenges, we have developed a new feed technology in conjunction with a unique fed-batch process that together has been shown not only to maximize protein titers but also to modulate glycan profiles.
Research And Development
Medical Laboratory Technician4%
Life Science Company6%
Manufacturer - Other3%